For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

If the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...

In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...

The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...

India started its inaugural phase 3 clinical trial for the DengiAll dengue vaccine, developed by Panacea Biotec. The trial will include 10,...

"We have decided to vaccinate 200 people from the 18-44 age category today at each of all the five centres and we have fully achieved this ...

The state had placed demand for 50 lakh vaccine doses in advance to launch the vaccination campaign for 1.57 crore population in the 18-44 ...

While more than 1.37 crore people registered themselves on April 28, more than 1.04 crore registered by the end of April 29.

"The country has administered more than 20 lakh vaccine doses till 8 pm today. Also, the total registrations on Co-Win portal for Phase-3 V...

"The phase III trials for the vaccine are underway and it has been tested on 30,000 healthy adult volunteers in India,” the executive said....

The governor further said that the Centre's Ayushman Bharat scheme, which provides free healthcare services, has provided succour to many a...

Speaking virtually at a programme organised by the Indian School of Business, Ella said the company is also working on another vaccine for ...

“India will have to focus on the indigenous vaccines and the AstraZeneca-Oxford vaccine. These vaccines are being tested in the India popul...

The vaccine 'Covaxin' is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (I...

According to officials, the Hyderabad-based vaccine maker applied to the Drugs Controller General of India (DCGI) on October 2, seeking its...

“We are planning to initiate a large phase 3 multicentre study to evaluate the efficacy and safety of the vaccine,” Bharat Biotech said in ...

While the country hopes to start mass-producing the vaccine by October and plans to offer the first doses to essential workers, many in the...